Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)
Close on Nov 17, 2026Market cap $4.82BP/E –Yield –
Travere Therapeutics cash
Cash and short-term investments held at the end of each period.
Travere Therapeutics's cash was $293.65M at Jun 30, 2026. For fiscal 2026 it was $238.42M, up 307.3% from the year before. Over ten years it grew 20.2% a year on average. The highest annual figure on record is $427.94M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Dec 31, 2025 | $238.42M | +307.3% |
| FY2025 | Dec 31, 2024 | $58.54M | -80.9% |
| FY2024 | Dec 31, 2023 | $306.81M | -11.6% |
| FY2023 | Dec 31, 2022 | $347.21M | -18.9% |
| FY2022 | Dec 31, 2021 | $427.94M | +20.0% |
| FY2021 | Dec 31, 2020 | $356.57M | +31.1% |
| FY2020 | Dec 31, 2019 | $271.93M | -12.7% |
| FY2019 | Dec 31, 2018 | $311.35M | +39.8% |
| FY2018 | Dec 31, 2017 | $222.67M | +443.1% |
| FY2017 | Dec 31, 2016 | $41.00M | +8.5% |
| FY2016 | Dec 31, 2015 | $37.81M | +107.7% |
| FY2015 | Dec 31, 2014 | $18.20M | +203.6% |
| FY2014 | Dec 31, 2013 | $6.00M | +153315.2% |
| FY2012 | Feb 29, 2012 | $3.91K | – |
| FY2011 | Feb 28, 2011 | $0 | -100.0% |
| FY2010 | Feb 28, 2010 | $4.65K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027 | Jun 30, 2026 | $293.65M | +290.7% |
| Q1 FY2027 | Mar 31, 2026 | $208.95M | +237.6% |
| Q4 FY2026 | Dec 31, 2025 | $238.42M | +307.3% |
| Q3 FY2026 | Sep 30, 2025 | $249.59M | -2.3% |
| Q2 FY2026 | Jun 30, 2025 | $75.15M | -70.4% |
| Q1 FY2026 | Mar 31, 2025 | $61.90M | -78.3% |
| Q4 FY2025 | Dec 31, 2024 | $58.54M | -80.9% |
| Q3 FY2025 | Sep 30, 2024 | $255.36M | -28.4% |
| Q2 FY2025 | Jun 30, 2024 | $253.94M | -15.9% |
| Q1 FY2025 | Mar 31, 2024 | $284.61M | -35.4% |
| Q4 FY2024 | Dec 31, 2023 | $306.81M | -11.6% |
| Q3 FY2024 | Sep 30, 2023 | $356.87M | -20.4% |
| Q2 FY2024 | Jun 30, 2023 | $301.98M | -40.6% |
| Q1 FY2024 | Mar 31, 2023 | $440.43M | -16.8% |
| Q4 FY2023 | Dec 31, 2022 | $347.21M | -18.9% |
| Q3 FY2023 | Sep 30, 2022 | $448.09M | -1.0% |
| Q2 FY2023 | Jun 30, 2022 | $508.78M | +23.6% |
| Q1 FY2023 | Mar 31, 2022 | $529.67M | +22.9% |
| Q4 FY2022 | Dec 31, 2021 | $427.94M | +20.0% |
| Q3 FY2022 | Sep 30, 2021 | $452.79M | +13.4% |
| Q2 FY2022 | Jun 30, 2021 | $411.54M | +11.1% |
| Q1 FY2022 | Mar 31, 2021 | $431.01M | +59.7% |
| Q4 FY2021 | Dec 31, 2020 | $356.57M | +31.1% |
| Q3 FY2021 | Sep 30, 2020 | $399.27M | +34.8% |
| Q2 FY2021 | Jun 30, 2020 | $370.29M | +24.1% |
| Q1 FY2021 | Mar 31, 2020 | $269.87M | -0.3% |
| Q4 FY2020 | Dec 31, 2019 | $271.93M | -12.7% |
| Q3 FY2020 | Sep 30, 2019 | $296.10M | -15.6% |
| Q2 FY2020 | Jun 30, 2019 | $298.37M | +234.1% |
| Q1 FY2020 | Mar 31, 2019 | $270.67M | +342.9% |
| Q4 FY2019 | Dec 31, 2018 | $311.35M | +39.8% |
| Q3 FY2019 | Sep 30, 2018 | $350.88M | +254.5% |
| Q2 FY2019 | Jun 30, 2018 | $89.31M | +0.0% |
| Q1 FY2019 | Mar 31, 2018 | $61.12M | +46.0% |
| Q4 FY2018 | Dec 31, 2017 | $222.67M | +443.1% |
| Q3 FY2018 | Sep 30, 2017 | $98.99M | +314.3% |
| Q2 FY2018 | Jun 30, 2017 | $89.27M | – |
| Q1 FY2018 | Mar 31, 2017 | $41.87M | – |
| Q4 FY2017 | Dec 31, 2016 | $41.00M | – |
| Q3 FY2017 | Sep 30, 2016 | $23.90M | – |
See a number that looks wrong?